The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The National Centre For Asbestos Related Diseases (NCARD)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The National Centre for Asbestos Related Diseases is a world-leading centre studying the deadly cancers mesothelioma and lung cancer. Our ongoing Centre of Research Excellence program includes research from the development and genetics of asbestos-related cancers, through to new treatments, novel ways of imaging cancer, and the supportive care of people with these cancers. This program will improve the detection, diagnosis, and treatment of mesothelioma and asbestos-related lung cancer.
Asia-Pacific Pneumococcal Disease Control In The Pneumococcal Conjugate Vaccine Era
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
Pneumonia is one of the commonest causes of childhood death worldwide. PCV is a vaccine that prevents pneumonia but it is costly; and causes an increase in disease from strains which are not in the vaccine. Our CRE will address 2 outstanding issues: when to switch from a 3 to 2 dose PCV schedule to make it more affordable; and create new understanding of the non-vaccine strains’ impact on disease in low- and middle-income countries in the Asia-Pacific region.
Optimising Early Interventions For Young People With Emerging Mood Disorder
Funder
National Health and Medical Research Council
Funding Amount
$2,653,052.00
Summary
One of our greatest health challenges is to develop highly-personalised interventions for teenagers and young adults with emerging mood disorders, like major depression or bipolar disorder. This new Australian centre combines our national expertise and links it with research innovation and training in key European and North American centres. It tests the viability of selecting the best treatments for young people with mood disorders on the basis of novel genetic, neuropsychological, circadian, i ....One of our greatest health challenges is to develop highly-personalised interventions for teenagers and young adults with emerging mood disorders, like major depression or bipolar disorder. This new Australian centre combines our national expertise and links it with research innovation and training in key European and North American centres. It tests the viability of selecting the best treatments for young people with mood disorders on the basis of novel genetic, neuropsychological, circadian, imaging, immunological or clinical methods.Read moreRead less
Improving The Immediate And Longer-Term Health Outcomes Of Preterm Infants
Funder
National Health and Medical Research Council
Funding Amount
$2,661,088.00
Summary
Premature babies develop health problems that persist throughout life and impact on mental, physical and social well-being. As all body systems are immature at birth, premature babies can develop one or many different health problems. Many factors before, during and after birth may influence the baby’s response to different treatments. Our collaborative research program seeks to understand the big picture, to help us design better treatments that improve long term outcomes after preterm birth.
Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.